Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant modified bacillus anthracis protective antigen for use in vaccines

a technology of recombinant modified bacillus anthracis and protective antigen, which is applied in the direction of antibody medical ingredients, immunological disorders, peptide sources, etc., can solve the problems of no defined vaccine-induced protective level and difficult standardization

Active Publication Date: 2013-03-07
UNITED STATES OF AMERICA
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although AVA has been shown to be effective against cutaneous infection in animals and humans and against inhalation anthrax by rhesus monkeys (12), it has several limitations: 1) AVA elicits relatively high degree of local and systemic adverse reactions probably mediated by variable amounts of undefined bacterial products, making standardization difficult; 2) the immunization schedule requires administration of six doses within an eighteen-month period, followed by annual boosters for those at risk; and 3) there is no defined vaccine-induced protective level of serum PA to evaluate new lots of vaccines.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant modified bacillus anthracis protective antigen for use in vaccines
  • Recombinant modified bacillus anthracis protective antigen for use in vaccines
  • Recombinant modified bacillus anthracis protective antigen for use in vaccines

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0105]In this example, the expression and the stability of two recombinant PA variants, PA-SNKE-ΔFF-E308D (SEQ ID NO: 4) and PA-N657A (SEQ ID NO: 5), were studied. These proteins were expressed in the non-sporogenic avirulent strain BH445. Initial results indicated that PA-SNKE-ΔFF-E308D (SEQ ID NO: 4), which lacks two proteolysis-sensitive sites, is more stable than PA-N657A (SEQ ID NO: 5). Process development was conducted to establish an efficient production and purification process for PA-SNKE-ΔFF-E308D (SEQ ID NO: 4). Various parameters such as pH, media composition, growth strategy, and protease inhibitors composition were analyzed. The production process chosen was based on batch growth of B. anthracis using tryptone and yeast extract as the only sources of carbon, pH control at 7.5, and antifoam 289. Optimal harvest time was found to be 14-18 hours after inoculation, and EDTA (5 mM) was added upon harvesting for proteolysis control. In one of the processes described herein, ...

example 2

Composition of the Vaccines

[0139]Four combinations of the recombinant (modified) protective antigen (“rPA”) were made: (1) rPA in PBS (“phosphate buffered saline”), (2) rPA in formalin, (3) rPA in aluminum hydroxide and (4) rPA in formalin and aluminum hydroxide. Another formulation of succinylated rPA was prepared and tested (data not shown).

example 3

Immunogenicity in Mice

[0140]The four formulations described above were immunogenic in mice, and induced antibody levels comparable to those induced by the currently licensed anthrax vaccine. The induced antibodies had anthrax toxin neutralizing activity. It is planned to evaluate these formulations in humans, and to choose the best one for use as a vaccine.

[0141]The data from the mice experiments are set forth in the tables 3 to 5 below:

TABLE 3Number of Mice and ImmunogenGroup NumberNumber of MiceImmunogen105611PA (2.5 μg)-Untreated105711PA (12.5 μg)-Untreated105811PA (2.5 μg) + Alum105910PASUCC 10:1.25 (2.5 μg)106010PASUCC 10:1.25 (12.5 μg)106110PASUCC 10:3 (2.5 μg)106210PASUCC 10:3 (12.5 μg)106310PA-Formalin 0.3 (2.5 μg)106410PA-Formalin 0.3 (12.5 μg)106510PA-Formalin 3.0 (2.5 μg)106610PA-Formalin 3.0 (12.5 μg)106710PA-Formalin 7.12 (2.5 μg)106810PA-Formalin 7.12 (12.5 μg)106911Anthrax Vaccine 0.1 ml107010Control

TABLE 4Antibody Levels and Neutralization TitersMiceμg / mlNeutral, Tit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and / or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.

Description

RELATED APPLICATION[0001]This is a divisional of U.S. application Ser. No. 10 / 638,006 filed Aug. 8, 2003, which claims the benefit under 35 USC §119(e) to Provisional Application No. 60 / 402,285 filed Aug. 9, 2002.FIELD OF THE INVENTION[0002]This invention relates to improved methods for preparing Bacillus anthracis mutants and for producing recombinant Bacillus anthracis protective antigen (PA) for use in vaccines.BACKGROUND OF THE INVENTION[0003]Anthrax, a potentially fatal disease, is caused by Bacillus anthracis. The virulence of this pathogen is mediated by a capsule of a poly-D-γ-glutamic acid and an exotoxin composed of three proteins (14, 16, 17). The three protein components are the protective antigen (PA, 82 KDa), lethal factor (LF, 90.2 KDa) and edema factor (EF, 88.8 KDa). These proteins, non-toxic by themselves, form lethal toxins when combined with an activated PA (16). The genes coding for these three protein components and the capsule are found in the endogenous plasm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/07A61P31/04A61P37/04A61K39/00C07K14/32C12N1/21
CPCA61K39/00C07K14/32A61K2039/53A61K2039/505A61P31/04A61P37/04
Inventor LEPPLA, STEPHEN H.ROSOVITZ, MARY JOROBBINS, JOHN B.SCHNEERSON, RACHELHSU, S. DANASHILOACH, JOSEPHRAMIREZ, DELIA M.
Owner UNITED STATES OF AMERICA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com